Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²

11 February 2025 : Original article

Umut Yılmaz

^1ABCDEF*, Şükran Erdem Nurcan

^2BC, Deniz Özmen

^1B, Ayşe Salihoğlu^1AB, Ahmet Emre Eşkazan^1ADE, Şeniz Öngören^1AB, Zafer Başlar^1BD, Teoman Soysal

^1ADF, Muhlis Cem Ar^1ADEF, Tuğrul Elverdi^1ACDEF

DOI: 10.12659/AOT.947186

Ann Transplant 2025; 30:e947186

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Logistic regression analysis for the risk of 2-year disease progression and 5-year mortality for the entire group.

Covariates	2-year PFS			5-year OS
Covariates	OR	95% CI	p	OR	95% CI	p
Age >60	0.9	0.6–1.2	0.43	1.1	0.7–1.6	0.69
Mel140	0.7	0.4–1.2	0.16	1.8	1.1–2.9	0.02
Presence of high-risk genetic anomaly	4.3	1.6–12.1	0.005	6.9	2.5–19.6	0.001
PR at the time of ASCT	1.5	0.8–2.7	0.18	1.8	0.9–3.7	0.09
2 or more LoT	1.2	0.7–2.1	0.47	0.9	0.5–1.7	0.75
PFS – progression free survival; OS – overall survival; OR – odds ratio; CI – confidence interval; Mel140 – melphalan 140 mg/m; PR – partial remission; LoT – line of therapy. .

Back to the Article